These are my concerns, articulated once again echoing concerns with management... not to mention the gibberish-PR’s that contradict themselves periodically which further seem to erode public confidence in what’s going on. Minimal transparency and despite p2 trial-completions across multiple fronts.. zero partnerships etc.
NOT good news, and it’s not disputable.
(I’m a supporter and a non-insignificant investor holding a ‘Long’ position, but also a realist).